Brigham and Women's Hospital, Boston, MA.
Brigham and Women's Hospital, Boston, MA.
Urol Oncol. 2020 Aug;38(8):678-681. doi: 10.1016/j.urolonc.2020.04.035. Epub 2020 May 20.
Chromophobe renal cell carcinoma (chRCC) represents 5% of all RCC. ChRCC appears to arise from the distal nephron, in contrast to clear cell RCC that arises from the proximal nephron. ChRCC is distinctive because the tumor cells contain abundant abnormal mitochondria, and frequently have loss of one copy of multiple chromosomes, with a low rate of somatic mutations. Here, we focus on recent discoveries related to genetic and metabolic factors that may promote the progression of chRCC and summarize how these findings may relate to the prognosis and treatment of chRCC.
嫌色细胞肾细胞癌(chRCC)占所有肾细胞癌的 5%。与起源于近端肾单位的透明细胞肾细胞癌不同,chRCC 似乎起源于远端肾单位。chRCC 的特点是肿瘤细胞含有丰富的异常线粒体,并且经常丢失多个染色体的一个拷贝,体细胞突变率低。在这里,我们重点介绍与遗传和代谢因素相关的最新发现,这些因素可能促进 chRCC 的进展,并总结这些发现与 chRCC 的预后和治疗的关系。